__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
Regular monitoring is important to assess treatment benefits and inform the decision to switch1,2
Monitoring milestones of BCR-ABL1 transcript levels by the IS (international scale) at 3, 6 and 12 months is essential to determine treatment interventions.1,2
In later lines of treatment, acceptable response cannot be formally defined, but a BCR-ABL1IS >1% is insufficient for optimal survival.1,2
Adapted from Smith G, et al. 20202; Hochhaus A, et al. 2020.1
For full details on monitoring, please see the ELN 2020 Guidelines and the Scemblix SmPC.
Even after MMR is achieved, monitoring of MMR should continue every 3–6 months1,2
Make monitoring and management effective
CCyR, complete cytogenetic remission; EMR, early molecular response; IS, international scale; MMR, major molecular response; MR, molecular response.
SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.3
For further information please refer to the Summary of Product Characteristics.
References
- Hochhaus A, et al. Leukemia 2020;34:966–984.
- Smith G, et al. Br J Haematol 2020;191(2):171–193.
- SCEMBLIX (asciminib) Summary of Product Characteristics.